English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Cefiderocol (S-649266) is a novel siderophore cephalosporin active against a wide variety of Gram-negative bacteria, not only Enterobacteriaceae but also non-fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter spp., including carbapenem-resistant strains. This potent activity is due to its efficient penetration through the outer membrane via active iron transporter systems and its high stability to both serine- and metallo-carbapenemases.This study evaluated the in vitro activity of cefiderocol and comparator agents against carbapenem-resistant clinical isolates collected from urinary track source in 2014–2016 from global countries. Methods /Methods Carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant (MDR) non-fermenters (defined as resistant to imipenem, ciprofloxacin and amikacin) were collected globally from 2014 to 2016 by IHMA Inc. A total of 226 Enterobacteriaceae, 44 Acinetobacter baumannii, 45 P. aeruginosa, 7 Stenotrophomonas maltophilia and 1 Burkholderia cepacia isolated from a urinary track source were tested. MICs were determined for cefiderocol, cefepime (FEP), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), ciprofloxacin (CIP), colistin (CST), and meropenem (MEM) by broth microdilution and interpreted according to CLSI 2016 guidelines. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller Hinton broth. Quality control testing was performed on each day of testing by using E. coli ATCC25922 and P. aeruginosa ATCC27853. Results MIC90 of cefiderocol against carbapenem-resistant Enterobacteriaceae, MDR P. aeruginosa, MDR A. baumannii, and S. maltophilia were 4 µg/mL or less. However, MEM, C/T and CZA had MIC90s of >64µg/mL. Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant Enterobacteriaceae, A. baumannii, and P. aeruginosa isolates collected from a UTI source. At 4 µg/mL or less, cefiderocol inhibited the growth of 95.8% of the isolates. Conclusion These results strongly indicated that cefiderocol is a promising candidate for the treatment of the serious infections caused by cUTI isolated Gram-negative bacteria including carbapenem-resistant strains. Disclosures M. Tsuji, Shionogi & Co.: Employee, Salary; M. Hackel, IHMA: Employee, Salary; R. Echols, Shionogi & CO., LTD.: Consultant, Consulting fee; Y. Yamano, Shionogi & Co.: Employee, Salary

open forum infectious diseases

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016